Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
3086 studies found for:    "Lymphoma, Non-Hodgkin"
Show Display Options
RSS Create an RSS feed from your search for:
"Lymphoma, Non-Hodgkin"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Bendamustine;   Drug: Bortezomib
2 Terminated Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Zevalin
3 Completed Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: recombinant human interleukin 21 and rituximab
4 Completed A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: interleukin-18, Rituxan, Rituximab
5 Recruiting Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Procedure: Stem cell infusion;   Procedure: TLI;   Drug: Anti-thymocyte globulin;   Drug: Solumedrol;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
6 Recruiting A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Vincristine;   Drug: Idarubicin;   Drug: Dexamethasone
7 Active, not recruiting Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Rituximab;   Drug: Lenalidomide;   Drug: Placebo
8 Not yet recruiting Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: RP4010
9 Not yet recruiting A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: TAK-659;   Drug: Bendamustine;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Lenalidomide;   Drug: Ibrutinib
10 Recruiting BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Busulfan;   Drug: Etoposide;   Drug: Bendamustine
11 Recruiting Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: ABP 798;   Drug: Rituximab
12 Recruiting Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Copanlisib (BAY 80-6946);   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Bendamustine;   Drug: Prednisone
13 Recruiting A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: LAM-002A
14 Recruiting Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BAY1862864
15 Recruiting A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: CC-122
16 Recruiting GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Obinutuzumab and Pixantrone
17 Not yet recruiting Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Cytokine-induced killer cells (CIK)
18 Recruiting ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: ESHAP-Imatinib
19 Active, not recruiting Phase III Copanlisib in Rituximab-refractory iNHL
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: BAY No. 80 6946;   Drug: Placebo
20 Active, not recruiting MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Mabthera/Rituxan During First-Line Treatment for Lymphoma.
Condition: Lymphoma, Non Hodgkin
Intervention: Drug: rituximab [MabThera/Rituxan]

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.